Actinogen announces achievement of clinically and statistically significant
superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
without meeting the primary endpoint of a cognition “Attention Composite”
Looks like we are on folks
Regards
DD
Ann: ACW XanaCIDD phase 2a trial topline results, page-5
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.004(12.9%) |
Mkt cap ! $73.21M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.1¢ | 2.7¢ | $938.0K | 33.18M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 2741829 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 643372 | 2 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |